Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2020

20.07.2020 | Review

Patient preferences for locoregional therapy in early-stage breast cancer

verfasst von: Christina A. Minami, Tari A. King, Elizabeth A. Mittendorf

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

With an increasing emphasis on patient-centered care, clinicians in subspecialties such as breast surgery and radiation oncology that offer multiple therapeutic options with equivalent outcomes are under increasing pressure to aid patients with the decision-making process. The aim of this review is to summarize existing studies that either evaluated factors in patient’s decision-making regarding locoregional therapy in early-stage breast cancer or evaluated benefit thresholds required to change therapy decisions.

Methods

A PubMed search to identify prospective or retrospective studies written in English reporting factors in patient decision-making regarding locoregional therapy in early-stage breast cancer was conducted. No restriction was placed on publication date. Studies that focused on breast reconstruction decisions or on patient preferences for decision-making involvement were excluded.

Results

A total of 39 studies were identified; 19 examining patient preferences for breast-conserving surgery versus mastectomy, 7 on preferences for contralateral prophylactic mastectomy, 2 on non-surgical options, 2 on the extent of axillary surgery, and 9 on radiation therapy decisions. Themes such as fear of recurrence, desire to avoid additional invasive therapy, and the importance of physician preference were common, but many studies also highlighted factors important to specific subpopulations of women.

Conclusions

Patient preference is difficult to define and measure, and heterogeneity across studies renders direct comparison difficult. Future work is needed to define women’s risk-thresholds for certain treatments, delve into the psychological factors that direct their decisions, and understand how patients’ valuations of risk interact with society’s.
Literatur
4.
Zurück zum Zitat Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241. https://doi.org/10.1056/NEJMoa022152 CrossRefPubMed Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241. https://​doi.​org/​10.​1056/​NEJMoa022152 CrossRefPubMed
5.
Zurück zum Zitat Neuman HSJ, Hanlon B et al (2018) Local recurrence rates after breast-conserving therapy in patients receiving modern era therapy. American Society of Breast Surgeons Annual Meeting. 2018: Abstract 403956. Presented May 4, 2018 Neuman HSJ, Hanlon B et al (2018) Local recurrence rates after breast-conserving therapy in patients receiving modern era therapy. American Society of Breast Surgeons Annual Meeting. 2018: Abstract 403956. Presented May 4, 2018
6.
Zurück zum Zitat Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716. https://doi.org/10.1016/s0140-6736(11)61629-2 CrossRefPubMed Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716. https://​doi.​org/​10.​1016/​s0140-6736(11)61629-2 CrossRefPubMed
8.
Zurück zum Zitat Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B (2012) Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer 118(8):1982–1988. https://doi.org/10.1002/cncr.26484 CrossRefPubMed Kiess AP, McArthur HL, Mahoney K, Patil S, Morris PG, Ho A, Hudis CA, McCormick B (2012) Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer. Cancer 118(8):1982–1988. https://​doi.​org/​10.​1002/​cncr.​26484 CrossRefPubMed
9.
Zurück zum Zitat Lanning RM, Morrow M, Riaz N, McArthur HL, Dang C, Moo TA, El-Tamer M, Krause K, Siu C, Hsu M, Zhang Z, Pei X, McCormick B, Powell SN, Ho A (2015) The effect of adjuvant trastuzumab on locoregional recurrence of human epidermal growth factor receptor 2-positive breast cancer treated with mastectomy. Ann Surg Oncol 22(8):2517–2525. https://doi.org/10.1245/s10434-014-4321-2 CrossRefPubMed Lanning RM, Morrow M, Riaz N, McArthur HL, Dang C, Moo TA, El-Tamer M, Krause K, Siu C, Hsu M, Zhang Z, Pei X, McCormick B, Powell SN, Ho A (2015) The effect of adjuvant trastuzumab on locoregional recurrence of human epidermal growth factor receptor 2-positive breast cancer treated with mastectomy. Ann Surg Oncol 22(8):2517–2525. https://​doi.​org/​10.​1245/​s10434-014-4321-2 CrossRefPubMed
10.
Zurück zum Zitat Voogd AC, van Oost FJ, Rutgers EJ, Elkhuizen PH, van Geel AN, Scheijmans LJ, van der Sangen MJ, Botke G, Hoekstra CJ, Jobsen JJ, van de Velde CJ, von Meyenfeldt MF, Tabak JM, Peterse JL, van de Vijver MJ, Coebergh JW, van Tienhoven G (2005) Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer 41(17):2637–2644. https://doi.org/10.1016/j.ejca.2005.04.040 CrossRefPubMed Voogd AC, van Oost FJ, Rutgers EJ, Elkhuizen PH, van Geel AN, Scheijmans LJ, van der Sangen MJ, Botke G, Hoekstra CJ, Jobsen JJ, van de Velde CJ, von Meyenfeldt MF, Tabak JM, Peterse JL, van de Vijver MJ, Coebergh JW, van Tienhoven G (2005) Long-term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer 41(17):2637–2644. https://​doi.​org/​10.​1016/​j.​ejca.​2005.​04.​040 CrossRefPubMed
22.
Zurück zum Zitat Hawley ST, Griffith KA, Hamilton AS, Ward KC, Morrow M, Janz NK, Katz SJ, Jagsi R (2017) The association between patient attitudes and values and the strength of consideration for contralateral prophylactic mastectomy in a population-based sample of breast cancer patients. Cancer 123(23):4547–4555. https://doi.org/10.1002/cncr.30924 CrossRefPubMed Hawley ST, Griffith KA, Hamilton AS, Ward KC, Morrow M, Janz NK, Katz SJ, Jagsi R (2017) The association between patient attitudes and values and the strength of consideration for contralateral prophylactic mastectomy in a population-based sample of breast cancer patients. Cancer 123(23):4547–4555. https://​doi.​org/​10.​1002/​cncr.​30924 CrossRefPubMed
32.
Zurück zum Zitat Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE (2007) Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25(24):3657–3663. https://doi.org/10.1200/jco.2006.07.4062 CrossRefPubMed Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE (2007) Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25(24):3657–3663. https://​doi.​org/​10.​1200/​jco.​2006.​07.​4062 CrossRefPubMed
34.
Zurück zum Zitat Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready DR, Mamounas EP, Costantino JP, Wolmark N (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8(10):881–888. https://doi.org/10.1016/s1470-2045(07)70278-4 CrossRefPubMed Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready DR, Mamounas EP, Costantino JP, Wolmark N (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8(10):881–888. https://​doi.​org/​10.​1016/​s1470-2045(07)70278-4 CrossRefPubMed
35.
Zurück zum Zitat Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A (2018) Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23–01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 19(10):1385–1393. https://doi.org/10.1016/S1470-2045(18)30380-2 CrossRefPubMed Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, Taffurelli M, Littlejohn D, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan MM, Coates AS, Gelber RD, Goldhirsch A (2018) Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23–01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol 19(10):1385–1393. https://​doi.​org/​10.​1016/​S1470-2045(18)30380-2 CrossRefPubMed
36.
Zurück zum Zitat Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310. https://doi.org/10.1016/s1470-2045(14)70460-7 CrossRefPubMedPubMedCentral Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ (2014) Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981–22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 15(12):1303–1310. https://​doi.​org/​10.​1016/​s1470-2045(14)70460-7 CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318(10):918–926. https://doi.org/10.1001/jama.2017.11470 CrossRefPubMedPubMedCentral Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M (2017) Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA 318(10):918–926. https://​doi.​org/​10.​1001/​jama.​2017.​11470 CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gelber RD, Coates AS (2006) Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10–93. J Clin Oncol 24(3):337–344. https://doi.org/10.1200/jco.2005.01.5784 CrossRefPubMed Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gelber RD, Coates AS (2006) Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10–93. J Clin Oncol 24(3):337–344. https://​doi.​org/​10.​1200/​jco.​2005.​01.​5784 CrossRefPubMed
46.
Zurück zum Zitat Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14(11):1086–1094. https://doi.org/10.1016/s1470-2045(13)70386-3 CrossRefPubMed Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR (2013) The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol 14(11):1086–1094. https://​doi.​org/​10.​1016/​s1470-2045(13)70386-3 CrossRefPubMed
47.
Zurück zum Zitat Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W, Grimard L, Bowen J, Lukka H, Perera F, Fyles A, Schneider K, Gulavita S, Freeman C (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362(6):513–520. https://doi.org/10.1056/NEJMoa0906260 CrossRefPubMed Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, Shelley W, Grimard L, Bowen J, Lukka H, Perera F, Fyles A, Schneider K, Gulavita S, Freeman C (2010) Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 362(6):513–520. https://​doi.​org/​10.​1056/​NEJMoa0906260 CrossRefPubMed
49.
Zurück zum Zitat Kawaguchi H, Tsujino K, Miki M, Matsumoto Y, Ota Y, Hirokaga K, Takao S, Soejima T, Sasaki R (2019) Patient preference study comparing hypofractionated versus conventionally fractionated whole-breast irradiation after breast-conserving surgery. Jpn J Clin Oncol 49(6):545–553. https://doi.org/10.1093/jjco/hyz003 CrossRefPubMed Kawaguchi H, Tsujino K, Miki M, Matsumoto Y, Ota Y, Hirokaga K, Takao S, Soejima T, Sasaki R (2019) Patient preference study comparing hypofractionated versus conventionally fractionated whole-breast irradiation after breast-conserving surgery. Jpn J Clin Oncol 49(6):545–553. https://​doi.​org/​10.​1093/​jjco/​hyz003 CrossRefPubMed
50.
Zurück zum Zitat Bonin K, McGuffin M, Presutti R, Harth T, Mesci A, Feldman-Stewart D, Chow E, DiProspero L, Vesprini D, Rakovitch E, Lee J, Paszat L et al (2018) Breast cancer patients' preferences for adjuvant radiotherapy post lumpectomy: whole breast irradiation vs partial breast irradiation-single institutional study. J Cancer Educ 33(1):37–43CrossRefPubMed Bonin K, McGuffin M, Presutti R, Harth T, Mesci A, Feldman-Stewart D, Chow E, DiProspero L, Vesprini D, Rakovitch E, Lee J, Paszat L et al (2018) Breast cancer patients' preferences for adjuvant radiotherapy post lumpectomy: whole breast irradiation vs partial breast irradiation-single institutional study. J Cancer Educ 33(1):37–43CrossRefPubMed
51.
Zurück zum Zitat Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sutterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HM, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M (2014) Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-a randomised trial. Lancet 383(9917):603–613. https://doi.org/10.1016/s0140-6736(13)61950-9 CrossRefPubMed Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sutterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HM, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M (2014) Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-a randomised trial. Lancet 383(9917):603–613. https://​doi.​org/​10.​1016/​s0140-6736(13)61950-9 CrossRefPubMed
54.
Zurück zum Zitat Corica T, Saunders CM, Bulsara MK, Taylor M, Joseph DJ, Nowak AK (2019) Patient preferences for adjuvant radiotherapy in early breast cancer are strongly influenced by treatment received through random assignment. Eur J Cancer Care (Engl) 28(2):e12985. https://doi.org/10.1111/ecc.12985 CrossRef Corica T, Saunders CM, Bulsara MK, Taylor M, Joseph DJ, Nowak AK (2019) Patient preferences for adjuvant radiotherapy in early breast cancer are strongly influenced by treatment received through random assignment. Eur J Cancer Care (Engl) 28(2):e12985. https://​doi.​org/​10.​1111/​ecc.​12985 CrossRef
58.
Zurück zum Zitat Russo S, Jongerius C, Faccio F, Pizzoli SFM, Pinto CA, Veldwijk J, Janssens R, Simons G, Falahee M, de Bekker-Grob E, Huys I, Postmus D, Kihlbom U, Pravettoni G (2019) Understanding patients' preferences: a systematic review of psychological instruments used in patients' preference and decision studies. Value Health 22(4):491–501. https://doi.org/10.1016/j.jval.2018.12.007 CrossRefPubMed Russo S, Jongerius C, Faccio F, Pizzoli SFM, Pinto CA, Veldwijk J, Janssens R, Simons G, Falahee M, de Bekker-Grob E, Huys I, Postmus D, Kihlbom U, Pravettoni G (2019) Understanding patients' preferences: a systematic review of psychological instruments used in patients' preference and decision studies. Value Health 22(4):491–501. https://​doi.​org/​10.​1016/​j.​jval.​2018.​12.​007 CrossRefPubMed
59.
Zurück zum Zitat Degner LF, Sloan JA, Venkatesh P (1997) The Control Preferences Scale. Can J Nurs Res 29(3):21–43PubMed Degner LF, Sloan JA, Venkatesh P (1997) The Control Preferences Scale. Can J Nurs Res 29(3):21–43PubMed
61.
Zurück zum Zitat Louviere J, Flynn T, Carson R (2010) Discrete choice experiments are not conjoint analysis. J Choice Model 3:57–72CrossRef Louviere J, Flynn T, Carson R (2010) Discrete choice experiments are not conjoint analysis. J Choice Model 3:57–72CrossRef
62.
Zurück zum Zitat Gafni A (1994) The standard gamble method: what is being measured and how it is interpreted. Health Serv Res 29(2):207–224PubMedPubMedCentral Gafni A (1994) The standard gamble method: what is being measured and how it is interpreted. Health Serv Res 29(2):207–224PubMedPubMedCentral
69.
Zurück zum Zitat Mandelblatt JS, Hadley J, Kerner JF, Schulman KA, Gold K, Dunmore-Griffith J, Edge S, Guadagnoli E, Lynch JJ, Meropol NJ, Weeks JC, Winn R (2000) Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer 89(3):561–573CrossRefPubMed Mandelblatt JS, Hadley J, Kerner JF, Schulman KA, Gold K, Dunmore-Griffith J, Edge S, Guadagnoli E, Lynch JJ, Meropol NJ, Weeks JC, Winn R (2000) Patterns of breast carcinoma treatment in older women: patient preference and clinical and physical influences. Cancer 89(3):561–573CrossRefPubMed
Metadaten
Titel
Patient preferences for locoregional therapy in early-stage breast cancer
verfasst von
Christina A. Minami
Tari A. King
Elizabeth A. Mittendorf
Publikationsdatum
20.07.2020
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-020-05737-9

Weitere Artikel der Ausgabe 2/2020

Breast Cancer Research and Treatment 2/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.